ClinicalTrials.gov
public full text
Public Domain
5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS
MULTICENTERS. Uncontrolled and open phase II study. Evaluation of the effectiveness of a treatment associating 5 Azacytidine,Valproic acid ,Retinoic Acid at subjects-reached of syndromes myelodysplasia and acute MYELOID leukaemia Hematological response at 6 months Uncontrolled prospective cohort.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome#1151729
- 5-Azacitidine in Low-risk Myelodysplastic Syndromes (MDSs)#1152512
- Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AML#1114177
- Azacytidine for the Treatment of Myelodysplastic Syndromes/Acute Myeloid Leukemia (MDS/AML) With High Risk (Chromosome 7 and or Complex) Cytogenetic Abnormalities#1112973
- High Risk Myelodysplasia Treated by Azacytidine : Genetic and Epigenetic (MYRAGE)#863614
Record · ID 861355
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive